Aclarion Inc (ACON)vsAstraZeneca PLC (AZN)
ACON
Aclarion Inc
$2.38
+0.85%
HEALTHCARE · Cap: $5.81M
AZN
AstraZeneca PLC
$157.97
-1.49%
HEALTHCARE · Cap: $263.09B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 78795486% more annual revenue ($61.37B vs $77,880). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
ACON
Avoid29
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$157.97
$38.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ACON profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.22 — expect wider price swings.
ACON is growing revenue faster at 11.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 29/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a pioneering healthcare technology firm dedicated to advancing non-invasive diagnostic solutions for musculoskeletal conditions through cutting-edge imaging and data analytics. By harnessing the power of machine learning, Aclarion empowers healthcare providers with actionable insights that not only improve clinical outcomes but also optimize treatment pathways and reduce costs. Positioned at the forefront of the digital health revolution, the company is well-equipped to meet the rising demand for effective diagnostics, thereby significantly enhancing patient management and care standards in a dynamic healthcare landscape. Aclarion's commitment to improving patient care underscores its vital role in the future of healthcare delivery.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?